50% off Premium Yearly

NYSE:CI
This summary was created by AI, based on 1 opinions in the last 12 months.
Cigna Corp. (CI-N) has received mixed reviews recently, with a focus on its performance following recent policy changes under the Trump administration that have negatively affected health maintenance organizations (HMOs) and pharmacy benefits managers. Experts are highlighting a common theme of compressing margins within the healthcare space. This pessimistic outlook suggests that the current overhang may persist for several more quarters, leading to a cautious approach among investors. The company was noted as a top pick in October 2024, despite a recent decline in stock value. Overall, there are significant concerns surrounding regulatory impacts and their potential effects on profitability.
Shares are down because the market fears they will do a tie-up deal with Humana, but CI bowed out. This is good given Human's problems. Managers are excellent, making good deals. EPS grew 13% compounded annual growth rate from 2013-2023. Are buying back shares and pay a dividend.
(Analysts’ price target is $397.05)(Top Pick Aug 17/16, Up 39.68%) A US based health insurance company. The news was that last year Anthem had made an offer for them, but he thought the takeover would not go through. There is a large break fee for the deal not going through. He thinks going forward they will buy back stock, invest and raise their dividend. It is another well run story.
A US health insurer provider, one of the largest. There is a pending deal. Aetna (AET-N) (?) wants to buy the company, and it is unlikely that deal gets approved. If the deal doesn’t get approved, the break fee is about $1.5 billion. On top of that, when you look at the cash they can deploy, they are going to have about $10 billion to play with. They can buy back a ton of stock if the deal does not go through. If it does go through, you still get 30% upside. Dividend yield of .03%.
Health care insurance space, global. A company wanted to buy them and it was rejected by the US government, but they have until next April for the deal to go through. 14 times earnings. They help companies save money. Once the deal does close, or doesn’t, they will have the ability to raise the dividend.
Cigna Corp. is a American stock, trading under the symbol CI (previously CI-N on Stockchase) on the New York Stock Exchange (CI). It is usually referred to as NYSE:CI or CI
In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on CI (previously CI-N on Stockchase). 1 analyst recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is BUY. Read the latest stock experts' ratings for Cigna Corp..
Cigna Corp. was recommended as a Top Pick by James Telfser on 2013-06-25. Read the latest stock experts ratings for Cigna Corp..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Cigna Corp..
Cigna Corp. is followed by 13 investors on Stockchase and is a trending stock that is worth watching.
On 2026-06-15, Cigna Corp. (CI) stock closed at a price of $295.38.
Sold last year, mainly because Trump administration announced seemingly negative measures toward HMO's in general and specific ones with pharmacy benefits managers. Common theme in the space is that margins are compressing. Overhang will go on for a few more quarters.